Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 11/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.42 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26907652 | 0.90 | MAP3K5 (0.42) | PIK3CAPIK3CGTGFBR1KDM4ENPC1 | |
| SCHEMBL17065966 | 0.86 | LRRK2 (0.49) | KDR | |
| SCHEMBL24286056 | 0.86 | F2 (0.42) | PIK3CAPIK3CGPIK3CDPIK3CBPIK3C3 | |
| SCHEMBL29770756 | 0.84 | AAK1 (0.42) | PIK3CAPIK3CGMAP3K5 | |
| SCHEMBL13784013 | 0.84 | PIK3CA (0.43) | PIK3CAPIK3CGTGFBR1PIK3CDPIK3CB | |
| SCHEMBL31204283 | 0.84 | OTUD7B (0.42) | PIK3CAPIK3CGMAP3K5 | |
| SCHEMBL22363009 | 0.82 | LRRK2 (0.57) | — | |
| SCHEMBL31204322 | 0.81 | OTUD7B (0.40) | PIK3CAPIK3CGMAP3K5 | |
| SCHEMBL1734165 | 0.78 | PTGS1 (0.46) | KDM4EPOLB | |
| SCHEMBL2926375 | 0.77 | PIK3CA (0.43) | PIK3CAPIK3CGPIK3CDPIK3CBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3487498-B1 | HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND APPLICATION THEREOF | ZHANG XIAOHU (CN) | 2023-09-06 | — | — | EP | disclosed |
| US-10815226-B2 | Heteroaryl compounds as inhibitors of necrosis, composition and application thereof | ACCRO BIOSCIENCE INC. (KY) | 2020-10-27 | — | — | US | disclosed |
| US-10815226-B2 | Heteroaryl compounds as inhibitors of necrosis, composition and application thereof | ACCRO BIOSCIENCE INC. (KY) | 2020-10-27 | — | — | US | disclosed |
| US-20190284180-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND APPLICATION THEREOF | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2019-09-19 | — | — | US | disclosed |
| US-20190284180-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND APPLICATION THEREOF | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2019-09-19 | — | — | US | disclosed |
| WO-2018017435-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND APPLICATION THEREOF | ACCRO BIOSCIENCE INC. (KY) | 2018-01-25 | — | — | WO | disclosed |
| US-7820665-B2 | Imidazopyridazine inhibitors of PI3 kinase for cancer treatment | AMGEN INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820665-B2 | Imidazopyridazine inhibitors of PI3 kinase for cancer treatment | AMGEN INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820665-B2 | Imidazopyridazine inhibitors of PI3 kinase for cancer treatment | AMGEN INC. (US) | 2010-10-26 | — | — | US | disclosed |
| EP-2231661-A1 | INHIBITORS OF PI3 KINASE | Amgen, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| WO-2009085230-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009085230-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090163489-A1 | Inhibitors of PI3 kinase | AMGEN INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090163489-A1 | Inhibitors of PI3 kinase | AMGEN INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090163489-A1 | Inhibitors of PI3 kinase | AMGEN INC. | 2009-06-25 | — | — | US | disclosed |
| EP-1989201-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007095588-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007095588-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3CG 4/4885TGFBR1 1388/4885 |
| US-10815226-B2 | Heteroaryl compounds as inhibitors of necrosis, composition and application thereof | LITAF, BAX, TNF | PIK3CA 553/4885PIK3CG 1116/4885TGFBR1 2893/4885 |
| US-20190284180-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND APPLICATION THEREOF | LITAF, BAX, TNF | PIK3CA 553/4885PIK3CG 1116/4885TGFBR1 2893/4885 |
| US-20090163489-A1 | Inhibitors of PI3 kinase | PIK3CA, PIK3CD, PIK3CG | PIK3CA 1/4885PIK3CG 3/4885TGFBR1 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.